Clarify
the Complexity
Rapid & Actionable Precision Therapy Insights. Driven by Data, Powered by AI, Guided by Oncologists.
The Clarified Precision Medicine Difference
With Clarified, oncologists can deliver rapid and actionable precision therapy decisions, supported by a Clarified expert consult. Clarified is the first fully scalable Molecular Tumor Board solution, providing curated, data-driven clinical recommendations to support oncologists making targeted therapy decisions. Our concise one-page report provides guideline-based expert answers and saves invaluable treatment time.
Clarified Precision Medicine
Data & Technology Guided By Oncologists
Our unique combination of proven technology and expert oncology guidance provides a level of precision medical care usually reserved for elite research institutions – ensuring that all oncology patients have access to highly effective, genomically-informed drug therapies.
Precision,
Targeted Care.
Clarified Precision Medicine’s scalable asynchronous Molecular Tumor Board and expert consult services utilize a medical practice backed by our proven AI technology platform to interpret genomic tumor profiling testing based on NCCN guidelines. Our expert medical group not only helps design the technology but oversees the entire process, from developing and updating the algorithm to providing a last-line review of all recommended treatments.
Here’s How It
Works:
Clarified analyzes genomic results from any testing lab and provides actionable, simplified therapeutic recommendations.
We provide a single-page report with ranked, guideline-based clinical recommendations within 48 hours or less.
All results are reviewed by board-certified precision oncology experts.
Our reports include key citations and expert reviewers.
In the United States, there are 18 million patients with a history of cancer and 1.9 million new cancer diagnoses each year. Patients who receive precision therapies have survival rates that are three times greater than those who do not. However, 75 percent of doctors say they need help interpreting genomic tests. Clarified provides clinicians with a rapid precision medicine consult for every patient.
Learn More
Greater
Therapeutic Benefit.
Greater
Value.
Clarified Precision Medicine connects physicians and their patients to effective treatments faster. By pairing guidelines-based AI algorithms with expert oncology oversight and results review, Clarified removes the guesswork from making therapeutic choices. The result: clinically-actionable precision therapy reports that lead to greater efficacy, lower costs, and improved ROI.
Higher Therapeutic Utilization Rates
Pharmaceutical companies invest billions to develop precision-medicine treatments, but these therapies are underutilized due to gaps in precision oncology expertise, clinical workflows not optimized for precision therapeutics, and a documented lack of experts to provide timely genomic interpretations. Clarified is collaborating with oncologists to ensure these effective, cutting-edge therapies are more widely accessible. Our goal – make evidence-based precision therapy quick and simple for every oncologist to prescribe.
Advanced Solutions
Our solutions turn tests into therapy. Together with leading precision oncology experts, Clarified’s technology make precision medicine and personalized treatments a routine part of clinical workflows and patient care. Our genomics-informed solutions include a suite of somatic, germline, and data-related products, including ClarifiedSelect, ClarifiedMTB, OncoGuardian, and ClarifiedData.
Expert Precision Medicine Leadership
The Clarified team is an elite collection of experienced practicing precision medicine clinicians. Clarified is composed of nationally recognized talent in Medical Oncology, Oncology Pharmacy, Data Integration, Genomics, Molecular Pathology, and Digital Health with over 100 years of collective experience. The Founders include Howard McLeod, PharmD, FASCO, FCCP; Lincoln Nadauld, MD PhD; Lisa Alderson, MBA; and Jody Simon, MS, RPH. The company is led by CEO Rajni Natesan, MD, MBA.